Hanne Prytz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hanne Prytz has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Sven Almer
Department of Medicine, Solna Karolinska Institutet Stockholm Sweden
4 shared publications - Einar Björnsson
Department of Internal Medicine, Section of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden
3 shared publications Ulrika Broomé
3 shared publications- Annika Bergquist
Unit of Gastroenterology and Rheumatology, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
2 shared publications Per Sangfelt
2 shared publications- Stefan Lindgren
Lund University, Sweden
2 shared publications
Latest Publications
- 25 December 2012
- Vol. 109 (46) , 2090-2
[Rare metabolic diseases can be manifested as liver disease].
- 25 December 2012
- Vol. 109 (46) , 2090-2
[Rare metabolic diseases can be manifested as liver disease].
- 22 July 2010
- Vol. 107 (21) , 1392-5
[Difficult to stop primary sclerosing cholangitis].
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5) , -854-854
T1871 The Prevalence of Elevated IgG4 Levels in Patients with Primary Sclerosing Cholangitis
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5) , -854-854
T1871 The Prevalence of Elevated IgG4 Levels in Patients with Primary Sclerosing Cholangitis
- 3 March 2007
- Vol. 104 (4) , 210-3
[Acute liver failure--rapid multidisciplinary management].
- 31 January 2007
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 18 (1) , 44-47
Abdominal tenderness in ascites patients indicates spontaneous bacterial peritonitis
- 31 January 2007
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 18 (1) , 44-47
Abdominal tenderness in ascites patients indicates spontaneous bacterial peritonitis
- 1 December 2006
- Published by Wolters Kluwer Health in Hepatology
- Vol. 44 (6) , 1572-1580
Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation
Five to 15% of patients with primary sclerosing cholangitis (PSC) develop cholangiocarcinoma (CC) with a median survival of 5 to 7 months, an outcome not significantly improved by liver transplantation. However, if CC is found incidentally during the procedure or in the explanted liver, 5-year survival rates of 35% are reported. A noninvasive method to detect CC small enough to allow for intended curative surgery is needed. Unfortunately, computed tomography (CT) and ultrasonography (US) have poor sensitivity for detection of CC in PSC; however, positron emission tomography (PET) using 2-[18F]fluoro-2-deoxy-D-glucose (FDG) differentiates well between CC and nonmalignant tissue. We examined whether PET findings are valid using a blinded study design comparing pretransplantation FDG-PET results with histology of explanted livers. Dynamic FDG-PET was performed in 24 consecutive patients with PSC within 2 weeks after listing for liver transplantation and with no evidence of malignancy on CT, magnetic resonance imaging, or ultrasonography. The PET Center staff was blinded to clinical findings, and surgeons and pathologists were blinded to the PET results. Three patients had CC that was correctly identified by PET. PET was negative in 1 patient with high-grade hilar duct dysplasia. In 20 patients without malignancies, PET was false positive in 1 patient with epitheloid granulomas in the liver. In conclusion , dynamic FDG-PET appears superior to conventional imaging techniques for both detection and exclusion of CC in advanced PSC. FDG-PET may be useful for screening for CC in the pretransplant evaluation of patients with PSC.
- 1 December 2006
- Published by Wolters Kluwer Health in Hepatology
- Vol. 44 (6) , 1572-1580
Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation
Five to 15% of patients with primary sclerosing cholangitis (PSC) develop cholangiocarcinoma (CC) with a median survival of 5 to 7 months, an outcome not significantly improved by liver transplantation. However, if CC is found incidentally during the procedure or in the explanted liver, 5-year survival rates of 35% are reported. A noninvasive method to detect CC small enough to allow for intended curative surgery is needed. Unfortunately, computed tomography (CT) and ultrasonography (US) have poor sensitivity for detection of CC in PSC; however, positron emission tomography (PET) using 2-[18F]fluoro-2-deoxy-D-glucose (FDG) differentiates well between CC and nonmalignant tissue. We examined whether PET findings are valid using a blinded study design comparing pretransplantation FDG-PET results with histology of explanted livers. Dynamic FDG-PET was performed in 24 consecutive patients with PSC within 2 weeks after listing for liver transplantation and with no evidence of malignancy on CT, magnetic resonance imaging, or ultrasonography. The PET Center staff was blinded to clinical findings, and surgeons and pathologists were blinded to the PET results. Three patients had CC that was correctly identified by PET. PET was negative in 1 patient with high-grade hilar duct dysplasia. In 20 patients without malignancies, PET was false positive in 1 patient with epitheloid granulomas in the liver. In conclusion , dynamic FDG-PET appears superior to conventional imaging techniques for both detection and exclusion of CC in advanced PSC. FDG-PET may be useful for screening for CC in the pretransplant evaluation of patients with PSC.